Stock Analysts’ updated eps estimates for Thursday, August 17th:
Airgain (NASDAQ:AIRG) was downgraded by analysts at Zacks Investment Research from a hold rating to a strong sell rating. According to Zacks, “Airgain, Inc. is a provider of embedded antenna technologies. It offers antennas for the devices which are deployed in carrier, enterprise and residential wireless networks and systems, including set top boxes, access points, routers, gateways, media adapters and digital televisions. The company also offers residential wireless local area network or wireless fidelity to carriers, original equipment manufacturers, original design manufacturers and system designers. Airgain, Inc. is based in San Diego, United States. “
Aldeyra Therapeutics (NASDAQ:ALDX) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Aldeyra Therapeutics, Inc. is a biotechnology company. The company’s products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. “
Cable One (NYSE:CABO) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Cable One, Inc. is a cable company. The Company provides internet, cable television and telephone service primarily in the United States. Cable One, Inc. is based in Phoenix, United States. “
Cumulus Media (NASDAQ:CMLS) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Cumulus Media, Inc. is a radio broadcasting company focused on acquiring, operating and developing radio stations in mid-size radio markets in the United States. They provide sales and marketing services under local marketing, management and consulting agreements. “
Cona Resources (TSE:CONA) had its target price cut by National Bank Financial from C$3.50 to C$3.25. The firm currently has a sector perform rating on the stock.
CSG Systems International (NASDAQ:CSGS) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “CSG Systems International Inc. is a leading provider of outsourced billing, customer care and print and mail solutions and services supporting the North American cable and direct broadcast satellite markets. CSG’s solutions support some of the world’s largest and most innovative providers of bundled multi-channel video, Internet, voice and IP-based services. CSG’s unique combination of solutions, services and expertise ensure that cable and satellite operators can continue to rapidly launch new service offerings, improve operational efficiencies and deliver a high-quality customer experience in a competitive and ever-changing marketplace. “
Curtiss-Wright Corporation (NYSE:CW) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $108.00 target price on the stock. According to Zacks, “CURTISS-WRIGHT CORP. produces precision components for the aerospace, industrial and marine companies. Aerospace components consist of control and actuation systems. Co. also provides shot-perring & heat treating for industrial markets and the target rock subsidiary produces engineered valves for the United States Navy. “
Commercewest Bank Com (NASDAQ:CWBK) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “CommerceWest Bank provides a wide range of specialized commercial banking and financial services to entrepreneurs and small- to mid-sized businesses in southern California. Headquartered in Irvine, California, the company offers basic and analyzed checking accounts, money market accounts, saving accounts, certificates of deposit, attorney client services, and escrow accounts. The banks lending portfolio includes lines of credit; term loans; multifamily, construction, and commercial real estate loans; equipment financing; asset-based lines of credit; small business administration loans; state guaranteed programs; and letter of credit. It also offers online banking services, such as balance transfers, stop payments, make loan payments, and loan transfers. The company also offers various cash management services, signature services, and turnaround services. Regional offices are located throughout Southern California in Orange County, Inland Empire and Los Angeles. “
Concordia International Corp. (NASDAQ:CXRX) (TSE:CXR) was downgraded by analysts at Zacks Investment Research from a hold rating to a strong sell rating. According to Zacks, “Concordia International Corp is a diverse pharmaceutical company which focused on legacy pharmaceutical products and orphan drugs. The company also markets orphan drugs through its Orphan Drug Division, currently consisting of Photofrin(R) for the treatment of certain rare forms of cancer, which is currently undergoing testing for potential new indications. Concordia International Corp, formerly known as Concordia Healthcare Corp, is headquartered in Oakville, Canada. “
CyberAgent (NASDAQ:CYGIY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “CyberAgent Inc. provides internet services. Its business portfolio includes blog media website, internet ad business, game services and investment development business for smartphones and PC. CyberAgent Inc. is headquartered in Tokyo, Japan. “
Cytokinetics, (NASDAQ:CYTK) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. “
The Descartes Systems Group (NASDAQ:DSGX) (TSE:DSG) had its hold rating reissued by analysts at BMO Capital Markets. The firm currently has a $26.00 price target on the stock.
Edison International (NYSE:EIX) had its buy rating reiterated by analysts at BMO Capital Markets. They currently have a $85.00 price target on the stock.
Greif Bros. Corporation (NYSE:GEF) had its hold rating reiterated by analysts at BMO Capital Markets. They currently have a $55.00 price target on the stock.
Horizon Pharma PLC (NASDAQ:HZNP) was given a $17.00 target price by analysts at Cantor Fitzgerald. The firm currently has a buy rating on the stock.
International Paper (NYSE:IP) had its buy rating reissued by analysts at BMO Capital Markets.
NCI (NASDAQ:NCIT) had its buy rating reaffirmed by analysts at Cowen and Company. The firm currently has a $24.00 target price on the stock.
Cantor Fitzgerald began coverage on shares of Opko Health (NASDAQ:OPK). They issued a buy rating and a $20.00 price target on the stock. The analysts wrote, “Expect Rayaldee sales to pick up the pace. Sales force expansion for Rayaldee is under way, and OPK has made substantial progress in obtaining formulary access for Rayaldee. With more-extensive insurance coverage, OPK is continuing to expand its field-based sales force to 70 representatives from the original 35. Also, on 6/22/17, OPK announced that the Kidney Disease Improving Global Outcomes (KDIGO) organization had updated its Clinical Practice Guidelines for the Diagnosis, Evaluation, Prevention and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).””
Wal-Mart Stores (NYSE:WMT) had its hold rating reissued by analysts at Wells Fargo & Company.
